by Portfolio Grader | July 12, 2013 4:00 pm
The ratings of three Pharmaceutical stocks are down this week, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
This week, VIVUS Inc. (NASDAQ:VVUS) falls to a D (“sell”), worse than last week’s grade of C (“hold”). VIVUS is a biopharmaceutical company engaged in the development and commercialization of therapeutic products for large underserved markets. VVUS also rates an F in Portfolio Grader’s specific subcategory of Equity. As of July 12, 2013, 29.3% of outstanding VIVUS Inc. shares were held short. For a full analysis of VVUS stock, visit Portfolio Grader.
This week, Cempra Inc.’s (NASDAQ:CEMP) rating worsens to a D from the company’s C rating a week ago. Cempra manufactures and markets pharmaceutical products. The stock gets F’s in Equity and Cash Flow. For more information, get Portfolio Grader’s complete analysis of CEMP stock.
Corcept Therapeutics’ (NASDAQ:CORT) rating falls this week to an F (“strong sell”), down from last week’s D (“sell”). Corcept Therapeutics engages in the discovery, development, and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders. The stock gets F’s in Equity and Cash Flow. To get an in-depth look at CORT, get Portfolio Grader’s complete analysis of CORT stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
Source URL: http://investorplace.com/2013/07/3-pharmaceutical-stocks-to-sell-now-vvus-cemp-cort-14/
Short URL: http://invstplc.com/1nuvdXZ
Copyright ©2017 InvestorPlace Media, LLC. All rights reserved. 700 Indian Springs Drive, Lancaster, PA 17601.